Medicine and Dentistry
Radiation Therapy
100%
Non Small Cell Lung Cancer
55%
Neoplasm
36%
Chemoradiotherapy
33%
Head and Neck Cancer
32%
Overall Survival
31%
Oncology
25%
Stereotactic Body Radiation Therapy
25%
Diseases
20%
Neck
17%
Lung Cancer
16%
Positron Emission Tomography
14%
Squamous Cell Carcinoma
13%
Paclitaxel
11%
Cancer
11%
Malignant Neoplasm
11%
Clinical Trial
11%
Arm
10%
Intensity Modulated Radiation Therapy
10%
Small Cell Lung Cancer
9%
Re-Irradiation
9%
Progression Free Survival
8%
Cisplatin
8%
Fluorodeoxyglucose F 18
8%
Carcinoma
8%
Treatment Planning
8%
Surgery
8%
Cyberknife
8%
Group Trial
8%
Distant Metastasis
8%
Carboplatin
8%
Survival Rate
7%
Brain Metastasis
7%
Recurrent Disease
7%
Chemoradiation Therapy
7%
Metastatic Carcinoma
7%
Fluorodeoxyglucose
7%
Drug Megadose
7%
Prognostic Factor
6%
Proton Therapy
6%
Radiation Oncology
6%
Primary Tumor
6%
Phase I Trials
5%
Phase II Trials
5%
Lymph Node
5%
Prostate Cancer
5%
Head and Neck Squamous Cell Carcinoma
5%
Acute Toxicity
5%
Keyphrases
Radiotherapy
38%
Head-and-neck Cancer
38%
Radiation Therapy
35%
Radiation Therapy Oncology Group
29%
Overall Survival
28%
Head-and-neck
26%
Non-small Cell Lung Cancer (NSCLC)
25%
Locally Advanced
25%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
22%
Local Control
15%
Tumor
14%
Stereotactic Body Radiotherapy
13%
Chemotherapy
13%
Squamous Cell Carcinoma of Head
12%
Paclitaxel
12%
Chemoradiation
12%
Brain Metastases
11%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
10%
Stereotactic Body Radiation Therapy
10%
Re-irradiation
10%
Distant Metastasis
10%
Lung Cancer
10%
Stage III Non-small Cell Lung Cancer
9%
Radiation Dose
9%
Progression-free Survival
8%
Chemoradiotherapy
8%
Advanced Non-small Cell Lung Carcinoma
8%
Phase I Trial
8%
Postoperative Radiotherapy
8%
Local-regional Control
7%
Phase II Trial
7%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
7%
Cisplatin
7%
NRG Oncology
7%
Prognostic Factors
6%
CyberKnife
6%
Acute Toxicity
6%
Non-small Cell Lung Cancer Patients
6%
Late Toxicity
6%
Definitive Chemoradiation
6%
Hazard Ratio
6%
Positron Emission Tomography
6%
Radiation Oncology
6%
Concurrent Chemoradiotherapy
6%
Dose-limiting Toxicity
6%
Intensity-modulated Radiotherapy
6%
Definitive Radiotherapy
5%
Carboplatin
5%
Glioblastoma
5%
Treatment Planning
5%